Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: A meta-analysis

International Journal of Clinical Practice

Volumn 66, Issue 10, 2012, Pages 917-923

  Cheng, J ^a   Zhang, X ^a   Tian, J ^a   Li, Q ^a   Chen, J ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN; OLMESARTAN; RAMIPRIL; TEMOCAPRIL;

ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FUNCTION; MEAN ARTERIAL PRESSURE; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARTERIAL PRESSURE; DRUG THERAPY, COMBINATION; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, IGA; HUMANS; KIDNEY DISEASES; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84866489775     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2012.02970.x     Document Type: Article

References (31)

1. Berger J, Hinglais N,. Les depots intercapillaires d'IgA-IgG. J Urol Nephrol 1968; 74: 694-5.
2. D'Amico G,. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med 1987; 245: 709-27. (Pubitemid 18047151)
3. Julian BA, Waldo FB, Rifai A, Mestecky J,. IgA nephropathy, the most common glomerulonephritis worldwide: a neglected disease in the United States? Am J Med 1988; 84: 129-32.
4. Levy M, Berger J,. Worldwide perspective of IgA nephropathy. Am J Kidney Dis 1988; 12: 340-7.
5. Schena FP,. Immunoglobulin A nephropathy with mild renal lesions: a call in the forest for the physicians and nephrologists. Am J Med 2001; 110: 499-500.
6. Rostoker G, Desvaux-Belghiti D, Pilatte Y, et al., Immunomodulation with low-dose immunoglobulins for moderate IgAN and Henoch-Schonlein purpura. Preliminary results of a prospective uncontrolled trial. Nephron 1995; 69: 327-34.
7. Samuels JA, Strippoli GF, Craig JC, et al., Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev 2003; (4): CD003965.
8. Barratt J, Feehally J,. IgA nephropathy. J Am Soc Nephrol 2005; 16: 2088-97. (Pubitemid 41716440)
9. Floege J, Eitner F,. Present and future therapy options in IgAnephropathy. J Nephrol 2005; 18: 354-61. (Pubitemid 41700096)
10. Cheng J, Zhang W, Zhang XH,. ACEI/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials. Int J Clin Pract 2009; 63 (6): 880-8.
11. Parmar MK, Torri V, Stewart L,. Extracting summary statistics to perform meta-analyses of the published literature for survival end-points. Stat Med 1998; 17: 2815-34. (Pubitemid 28562978)
12. Mantel N, Haenszel W,. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-48.
13. Fleiss JL,. Analysis of data from multiclinic trials. Control Clin Trials 1986; 7: 267-75. (Pubitemid 17204882)
14. DerSimonian R, Laird N,. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88. (Pubitemid 17189972)
15. Hardy RJ, Thompson SG,. Detecting and describing heterogeneity in meta-analysis. Statist Med 1998; 17: 841-56. (Pubitemid 28185164)
16. Song JH, Lee SW, Suh JH,. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy. Clin Nephrol 2003; 60 (5): 318-26. (Pubitemid 37407689)
17. Russo D, Minutolo R, Pisani A,. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001; 38 (1): 18-25. (Pubitemid 32611753)
18. Horita Y, Taura K, Taguchi T,. Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy. Nephrology (Carlton) 2006; 11 (5): 462-6. (Pubitemid 44470097)
19. Horita Y, Tadokoro M, Taura K,. Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy. Hypertens Res 2004; 27 (12): 963-70. (Pubitemid 40425399)
20. Nakamura T, Inoue T, Sugaya T,. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephropathy. Am J Hypertens 2007; 20 (11): 1195-201. (Pubitemid 47588815)
21. Kim MJ, Song JH, Suh JH, Lee SW, Kim GA,. Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy. Yonsei Med J 2003; 44 (3): 463-72. (Pubitemid 36833898)
22. Strippoli GF, Manno C, Schena FP,. An 'evi-dence-based' survey of therapeutic options for IgA nephropathy: assessment and criticism. Am J Kidney Dis 2003; 41: 1129-39. (Pubitemid 36637967)
23. Samuels JA, Strippoli GF, Craig JC, et al., Immunosuppressive treatments for immunoglobulin A nephropathy: a meta-analysis of randomized controlled trials. Nephrology (Carlton) 2004; 9: 177-85. (Pubitemid 39318639)
24. Kawamura T,. Treatment of IgA nephropathy: glucocorticoids, tonsillectomy, and mycophenolate mofetil. Contrib Nephrol 2007; 157: 37-43.
25. Navaneethan SD, Viswanathan G, Strippoli GF,. Meta-analysis of mycophenolate mofetil in IgA nephropathy. Nephrology (Carlton) 2008; 13: 90.
26. Mogensen CE, Neldam S, Tikkanen I, et al., Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321 (7274): 1440-4.
27. Mann JF, Schmieder RE, McQueen M, et al., Renal outcomeswith telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-53.
28. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T,. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361 (9352): 117-24. Erratum in: Lancet 2003 Apr 5; 361 (9364): 1230. Retraction in: Lancet 2009 Oct 10; 374 (9697): 1226. (Pubitemid 36092015)
29. Parving HH, Brenner BM, McMurray JJ, et al., Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant. 2009; 24 (5): 1663-71. Epub 2009 Jan 14
30. Hebert LA, Wilmer WA, Falkenhain ME, et al., Renoprotection:One or many therapies? Kidney Int 2001; 59: 1211-26.
31. Wilmer WA, Rovin BH, Herbert CJ, et al., Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 2003; 14: 3217-32. (Pubitemid 37509297)